Accepting Cases

Viberzi Lawsuits

Patients who developed pancreatitis while taking Viberzi are filing lawsuits against the drug’s maker. Viberzi lawsuits claim Allergan failed to warn doctors that the drug increases the risk of pancreatitis in patients who don’t have a gallbladder.

When Erin Duncan was prescribed Viberzi in 2016, she hoped the medication would relieve her symptoms of irritable bowel syndrome. But after taking just one dose of the drug, the 46-year-old California woman landed in the hospital.

Lab tests and imaging showed that Duncan was suffering from acute pancreatitis, an inflammation of the pancreas. The condition is serious and sometimes deadly. It can lead to complications such as kidney failure, respiratory failure, diabetes and pancreatic cancer — and Duncan says Viberzi maker Allergan is entirely to blame.

In September 2018, Duncan filed an eight-count lawsuit against Allergan in U.S. District Court for the Central District of California.

In her suit, she alleges the drugmaker failed to “adequately test for and warn” that Viberzi created an increased risk of pancreatitis in patients like herself who don’t have gallbladders.

Though Duncan was discharged from the hospital after four days, she says she “remains at an increased risk” for recurrent attacks of pancreatitis and lives in fear she may one day develop pancreatic cancer because of the inflammation.

As of early October 2018, Allergan had not yet responded to the initial complaint filed by Duncan, which is among the first Viberzi suits filed over the drug’s side effects.

The company had 21 days to respond to the allegations, according to court filings.

Similar lawsuits could follow. According to the FDA, outpatient retail pharmacies in the U.S. dispensed about 64,000 Viberzi prescriptions from May 2015 through July 2016, though it’s unclear how many people developed pancreatitis while taking the drug.

Did you develop pancreatitis while taking Viberzi? Review Your Legal Options

Gallbladder Problems Spark FDA Warning

When the FDA approved Viberzi in 2015, the drug was hailed by its manufacturers as a “first step to providing physicians with a new, evidence-based, treatment option” for adults with irritable bowel syndrome with diarrhea (IBS-D).

But nearly two years later, in March 2017, the FDA issued a warning that the drug should not be used in patients who’ve had their gallbladders removed.

Did You Know?
In April 2017, Allergan changed Viberzi’s prescribing label to warn that the drug should not be used in patients without a gallbladder.
Source: U.S. Food & Drug Administration

The regulatory agency said it had received 120 reports between May 2015 and February 2017 of patients who’d developed serious cases of pancreatitis while taking Viberzi. Seventy-six of those patients ended up in the hospital and two died. At least 56 of the ill patients — including the two who died — did not have their gallbladders.

The European Medicines Agency, the European Union’s equivalent to the FDA, issued similar warnings about the drug even earlier, in July 2016.

Reports to FDA Between May 2015 & February 2017

Suit Says Clinical Trials Raised Red Flags

Litigants, such as Duncan, allege that there were signs of potential problems with the drug even before the FDA warning — and contend that the drugmaker did not properly investigate them.

Duncan’s complaint notes that at least 40 patients participating in Vibrezi clinical trials stopped taking the drug because of abdominal pain. According to the lawsuit, half of those events occurred during the first 24 hours of therapy, but the “vast majority” of those patients were not tested to see if they were suffering from pancreatitis.

“Properly designed and executed clinical trials would have led the original May 2015 label to contraindicate use in patients without gallbladders, Because the FDA did not have the benefit of data from adequately designed and executed clinical trials, it did not require contraindication in patients without a gallbladder.”

Source: Erin Duncan v. Allergan Inc. Case 2:18-cv-08047-FMO-E

Please seek the advice of a medical professional before making health care decisions.

Related Pages
Nurse Amy Keller
Written By Amy Keller Registered Nurse

Amy Keller is a registered nurse and award-winning journalist with 22 years of experience writing about politics, business, health and other topics. At Drugwatch, she draws on her clinical experience and investigative reporting skills to write about consumers’ health concerns such as the safety of online pharmacies. She also provides informed analysis on complex health issues. Some of her qualifications include:

  • Recipient of USF’s Nurse Alumni Nightingale award for excellence in nursing
  • Guest Faculty Speaker, “Moving Forward with Patient- and Family-Centered Care Intensive Training Seminar”
  • Member of Sigma Theta Tau International Honor Society of Nursing
Edited By

6 Cited Research Articles

  1. Allergan. (2015, May 27). Actavis Receives FDA Approval for Viberzi (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults. Retrieved from https://www.allergan.com/news/news/thomson-reuters/actavis-receives-fda-approval-for-viberzi-eluxadol
  2. Erin Duncan v. Allergan Inc. (2018, September 17). Case 2:18-cv-08047-FMO-E. Complaint and Demand for Jury Trial. United States District Court for the Central District of California. Retrieved from http://www.pacer.gov
  3. Mallari-Torres, J. (2018, September 19). Woman Alleges Medication Viberzi Caused Acute Pancreatitis. Retrieved from https://norcalrecord.com/stories/511578192-woman-alleges-medication-viberzi-caused-acute-pancreatitis
  4. U.S. Food & Drug Administration. (2017, March 15). FDA Drug Safety Communication: FDA Warns About Serious Pancreatitis with Irritable Bowel Drug Viberzi (eluxadoline) in Patients Without a Gallbladder. Retrieved from https://www.fda.gov/Drugs/DrugSafety/ucm546154.htm
  5. U.S. Food & Drug Administration. (2015, May 27). Approval Package for Application Number: 206940Orig1s000. Center for Drug Evaluation and Research. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206940Orig1s000Approv.pdf
  6. U.S. Food & Drug Administration. (2015, May 27). Application Number: 206940Orig1s000 Labeling. Center for Drug Evaluation and Research. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206940Orig1s000LBL.pdf
View All Sources
Who Am I Calling?

Calling this number connects you with Wilson and Peterson, LLP or one of its trusted legal partners. A law firm representative will review your case for free.

Wilson and Peterson, LLP funds Drugwatch because it supports the organization’s mission to keep people safe from dangerous drugs and medical devices.

(855) 781-7449